Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review

BACKGROUND: Advanced ALK-rearranged non-small cell lung cancer (NSCLC) patients will develop acquired resistance after anaplastic lymphoma kinase (ALK) inhibitors therapies. Vascular endothelial growth factor-A (VEGF-A) production and tumor vessel formation were found to be more significantly enrich...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhichao, Bao, Youting, Li, Butuo, Sun, Xindong, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760484/
https://www.ncbi.nlm.nih.gov/pubmed/29318404
http://dx.doi.org/10.1186/s40169-017-0178-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760484/
https://www.ncbi.nlm.nih.gov/pubmed/29318404
http://dx.doi.org/10.1186/s40169-017-0178-x

Ejemplares similares